Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Spikevax XBB.1.5
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
mRNA-1273.815 is a monovalent messenger RNA (mRNA) vaccine developed by ModernaTX, Inc., specifically designed to target the spike protein of the SARS-CoV-2 Omicron XBB.1.5 sublineage. It consists of a synthetic mRNA sequence encoding the viral spike protein, encapsulated within lipid nanoparticles (LNPs) for delivery. Upon intramuscular administration, the LNPs facilitate the entry of mRNA into host cells, which then translate the genetic information to produce the spike protein, eliciting a robust immune response including the production of neutralizing antibodies and T-cell activation. This vaccine was approved by the FDA in September 2023 as part of the 2023-2024 COVID-19 vaccine formulation series for individuals aged 6 months and older.
- Brand names
- Spikevax XBB.1.5
- Other names
- Moderna COVID-19 Vaccine (2023-2024 Formula)andusomeranmonovalent XBB.1.5 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on Spikevax XBB.1.5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spikevax XBB.1.5.